Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Glenmark Pharmaceuticals ltd Capital/Financing Update 2021

Apr 16, 2021

62608_rns_2021-04-17_31266cde-b6fc-44de-aae0-1bc7b5ff44f4.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [16 x 9] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 43] intentionally omitted <==

16 April 2021

To,Dy. General ManagerDepartment of Corporate Services,BSE Ltd.Phiroze Jeejeebhoy TowersDalal Street, Fort, Mumbai – 400 001Ref: Scrip Code: 532296 To,The Manager – ListingNational Stock Exchange of India Ltd.,Plot No. C/1, G Block,Bandra Kurla Complex,Bandra (E), Mumbai – 400 051Ref: Scrip Name: GLENMARK

Dear Sirs,

Re: Proposed Initial Public Offering (“IPO”) of Glenmark Life Sciences Limited‐ Filing of draft red herring prospectus

We wish to inform you that Glenmark Life Sciences Limited, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has today, i.e. on April 16, 2021, filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer, comprising of a fresh issue of up to ₹11,600 million and an offer for sale of up to 7,305,245 equity shares of ₹2 each of Glenmark Life Sciences Limited, by Glenmark Pharmaceuticals Limited (“ Offer ”).

In connection with the aforementioned Offer, the board of directors of Glenmark Pharmaceuticals Limited, at its meeting held today, i.e. April 16, 2021, accorded its approval for the offer for sale of up to 7,305,245 equity shares of ₹2, in the Offer.

The IPO will be subject to market conditions, receipt of applicable approvals and other considerations.

The above is for your information, records and dissemination.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

==> picture [67 x 43] intentionally omitted <==

Harish Kuber

Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [email protected]